---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-117568"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2024-10-28T23:59:59+00:00"
generated_at: "2026-05-30T09:37:06.108393+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# EyePoint reports positive Phase 2 VERONA interim data for DURAVYU in DME; +8.9 letters BCVA

## Summary
- DURAVYU 2.7mg showed +8.9 letter improvement in BCVA vs +3.2 for aflibercept control at 16 weeks.
- CST reduction of 68.1 microns vs 30.5 microns for control.
- 82% of DURAVYU 2.7mg eyes were supplement-free vs 50% for control at 16 weeks.
- No DURAVYU-related ocular or systemic SAEs reported; no endophthalmitis, vasculitis, or IOI.
- Full topline data from VERONA expected in Q1 2025.

## SEC filing metadata
- accession: 0000950170-24-117568
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2024-10-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017024117568/0000950170-24-117568-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017024117568/eypt-20241028.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-117568
- JSON: https://secwatch.observer/filing/0000950170-24-117568.json
- Plain text: https://secwatch.observer/filing/0000950170-24-117568.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.